Pharmaceuticals
Ireland’s Horizon Pharma launches $3-bn hostile buyout bid for US rival Depomed
08 Jul 2015
The combined entity will have 13 marketed drugs, which nearly doubles Horizon’s current portfolio of seven,and is expected to result in 2015 net sales of over $950 million
Teva plans to raise bid for rival drugmaker Mylan to $42 bn
07 Jul 2015
Teva and Mylan's product offerings are highly complementary and, together, would create the broadest portfolio in the global pharmaceuticals industry, with a combined pipeline of over 400 applications for new drugs
Biogen ventures into ophthalmology with $1-bn AGTC tie-up
04 Jul 2015
The collaboration will focus on the development of a portfolio of therapeutic programmes for orphan diseases of the retina that can lead to blindness in children and adults
US claims $3.3 bn in Novartis kickback lawsuit
01 Jul 2015
Novartis is accused of referring patients to specialty pharmacies and paying kickbacks in the form of rebates to get them to recommend the drugs to patients to boost sales
Novartis to buy chronic pain drug developer Spinifex Pharmaceuticals
29 Jun 2015
Founded in 2005 and based in Stamford, Connecticut, USA, and Melbourne, Australia, Spinifex’ lead product is EMA401, under development as a potential first-in-class oral treatment for chronic pain without CNS side effects
